MX2020002312A - Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin. - Google Patents

Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin.

Info

Publication number
MX2020002312A
MX2020002312A MX2020002312A MX2020002312A MX2020002312A MX 2020002312 A MX2020002312 A MX 2020002312A MX 2020002312 A MX2020002312 A MX 2020002312A MX 2020002312 A MX2020002312 A MX 2020002312A MX 2020002312 A MX2020002312 A MX 2020002312A
Authority
MX
Mexico
Prior art keywords
dapagliflozin
metformin
proline
pharmaceutical formulation
combined pharmaceutical
Prior art date
Application number
MX2020002312A
Other languages
Spanish (es)
Inventor
Yong Il Kim
Taek Kwan Kwon
Jung Hyun Cho
Hyung Seo Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180079614A external-priority patent/KR102369679B1/en
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2020002312A publication Critical patent/MX2020002312A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Abstract

The present invention relates to a combined formulation comprising dapagliflozin L-proline and metformin both. A combined formulation according to the present invention is advantageous for long-term medication because the formulation exhibits not only improved storage stability and property stability and an excellent dissolution rate, but also is highly convenient for dosage. In addition, the combined formulation can be useful for prevention or treatment of diabetes, diabetes-related disease, or diabetic complications.
MX2020002312A 2017-09-29 2018-09-18 Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin. MX2020002312A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170126878 2017-09-29
KR1020180079614A KR102369679B1 (en) 2017-09-29 2018-07-09 Pharmaceutical combination comprising DAPAGLIFLOZIN L-PROLINE and METFORMIN
PCT/KR2018/011004 WO2019066359A2 (en) 2017-09-29 2018-09-18 Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin

Publications (1)

Publication Number Publication Date
MX2020002312A true MX2020002312A (en) 2020-09-17

Family

ID=65901595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002312A MX2020002312A (en) 2017-09-29 2018-09-18 Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin.

Country Status (3)

Country Link
MX (1) MX2020002312A (en)
WO (1) WO2019066359A2 (en)
ZA (1) ZA202001892B (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
ES2856888T3 (en) * 2009-11-13 2021-09-28 Astrazeneca Ab Bilayer tablet formulations
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
KR101526825B1 (en) * 2014-12-23 2015-06-08 주식회사 한독 Pharmaceutical Compositions for The Treatment of Diabetes
CN106924208A (en) * 2015-12-30 2017-07-07 深圳翰宇药业股份有限公司 A kind of compound Dapagliflozin Metformin Extended-release Tablets and preparation method thereof

Also Published As

Publication number Publication date
WO2019066359A2 (en) 2019-04-04
WO2019066359A3 (en) 2019-05-16
ZA202001892B (en) 2023-06-28

Similar Documents

Publication Publication Date Title
IL279040A (en) Pharmaceutical combination and composition, and combination preparation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof
PH12017501222A1 (en) Glucagon derivatives with improved stability
WO2014144130A3 (en) Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
EA201201617A1 (en) APPLICATION OF METMORPHINE IN COMBINATION WITH GLUCOKINASE ACTIVATOR AND COMPOSITIONS CONTAINING METMORPHIN AND GLUCOKINASE ACTIVATOR
MX336657B (en) Prevention of hypoglycaemia in diabetes mellitus type 2 patients.
PH12019502655A1 (en) Acylated insulin compound
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
MX2018002223A (en) Novel insulin derivatives and the medical uses hereof.
PH12019501363A1 (en) Insulin containing pharmaceutical compositions
JP2017502074A5 (en)
JOP20210201A1 (en) Blood glucose lowering compound
PH12015501373A1 (en) Injectable depot formulation comprising optically active tolvaptan and process of producing the same
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
WO2018097570A3 (en) Pharmaceutical formulation comprising dapagliflozin l-proline
PH12020500532A1 (en) Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin
PH12018500817A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
MX2020002312A (en) Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin.
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
MX2018011293A (en) Prolonged release pharmaceutical composition comprising cysteamine or salt thereof.
WO2016126026A3 (en) Composition for treating diabetes and use thereof
PL414785A1 (en) 3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance
WO2014195900A3 (en) Oral pharmaceutical compositions for use in dyslipidemias
NZ724595A (en) Glucokinase activator compositions for the treatment of diabetes
MDS20160124U2 (en) Method for prophylaxis of prolonged lymphorrhagia in the radical treatment of breast cancer in patients with type 2 diabetes
MD4537B1 (en) Injectable supersaturated acetaminophen solution for spinal administration